D-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS

Gynecological Endocrinology

Volumn 31, Issue 6, 2015, Pages 483-486

  Cianci, Antonio ^a   Panella, Marco ^a   Fichera, Michele ^a   Falduzzi, Cristina ^a   Bartolo, Manuela ^a   Caruso, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alpha lipoic acid; Amenorrhea; d chiro inositol; PCOS

Indexed keywords

D CHIRO INOSITOL; INOSITOL DERIVATIVE; INSULIN; THIOCTIC ACID; UNCLASSIFIED DRUG; INOSITOL; VITAMIN B COMPLEX;

ACNE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HIRSUTISM; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; METABOLIC DISORDER; OVARY CYST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEBORRHEA; SHORT COURSE THERAPY; TREATMENT OUTCOME; ADOLESCENT; COMBINATION DRUG THERAPY; COMPLICATION; MENSTRUATION DISTURBANCES; METABOLIC SYNDROME X; YOUNG ADULT;

ADOLESCENT; ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INOSITOL; MENSTRUATION DISTURBANCES; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; THIOCTIC ACID; TREATMENT OUTCOME; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 84938089928     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2015.1014784     Document Type: Article

References (32)

1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
2. Hahn S, Bering van Halteren W, Kimmig R, et al. Diagnostic procedures in polycystic ovary syndrome. J Lab Med 2003;27:53-9.
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352: 1223-36.
4. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006;21:1400-7.
5. Ciotta L, Calogero AE, Farina M, et al. Clinical, endocrine and metabolic effects of acarbose: an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod 2001;16:2066-72.
6. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-32.
7. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.
8. Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-15.
9. Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 2010;4:359-64.
10. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407-13.
11. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8: 127-36.
12. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-44.
13. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of alpha-lipoic acid. Endocr Pract 2002;8:29-35.
14. Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 2010;4:359-64.
15. Capasso I, Esposito E, Maurea N, et al. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials 2013;14:273-9.
16. The Rotterdam ESHRE/ARSM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus ion diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
17. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999;71: 319-22.
18. Dinicola S, Chiu TT, Unfer V, et al. The rationale of the myoinositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 2014;54:1079-92.
19. Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014;30:438-43.
20. Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2014; 18:1896-903.
21. Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013;40:51-63.
22. Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet 2014;31:1269-76.
23. Desai V, Prasad NR, Manohar SM, et al. Oxidative stress in nonobese women with polycystic ovarian syndrome. J Clin Diagn Res 2014;8:CC01-3.
24. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336: 1066-71.
25. Uzel N, Sivas A, Uysal M, Oz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. Horm Metab Res 1987;19:89-90.
26. Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod 1997;12:53-62.
27. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84: 165-9.
28. Genazzani AD, Despini G, Santagni S, et al. Effects of a Combination of Alpha Lipoic Acid and Myo-Inositol on Insulin Dynamics in Overweight/Obese Patients with PCOS. Endocrinol Metab Syndr 2014;3:140.
29. Cappelli V, Di Sabatino A, Musacchio MC, De Leo V. Evaluation of a new association between insulin-sensitizers and a-lipoic acid in obese women affected by PCOS. Minerva Ginecol 2013;65:425-33.
30. Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000;2:401-13.
31. Asemi Z, Samimi M, Tabassi Z, et al. Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized clinical trial. Nutrition 2014;30:1287-93.
32. La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2014;30:1-5.